$VTGN up 16% and looks like it wants more 👀 🔹 Late-stage neuroscience biotech focused on intranasal “pherine” treatments for CNS disorders 🧠 🔹 Lead asset fa

$VTGN up 16% and looks like it wants more 👀 🔹 Late-stage neuroscience biotech focused on intranasal “pherine” treatments for CNS disorders 🧠 🔹 Lead asset fasedienol targets acute treatment of social anxiety disorder — a huge unmet market 🔹 PALISADE Phase 3 program remains the key catalyst trade…